Αρχική World News Droplet Transmission vs. Airborne… What’s the difference?

Droplet Transmission vs. Airborne… What’s the difference?

We have all seen in the news that there is still lots of discussion about how COVID-19 is really transmitted from person to person. Is it transmitted by droplet or by airborne transmission? The current stance is that it is transmitted through droplets, but researchers are not fully convinced that this is the only way COVID-19 is being spread from person to person. I’m sure at this point you might be a little perplexed or maybe you are still having a hard time understanding the need for masks. Rest assured that wearing a mask is not a hoax! Using a mask properly protects from droplet transmission of the virus.

So, what’s the difference between droplet and airborne?

Droplet: Germs travel in the droplets (small moist particles) that are released when:

  • Coughing
  • Sneezing
  • Talking
  • Close contact with an infected person

There are some other common virus/infections that you are familiar with that are also transmitted via droplet transmission, which include:

  • Pneumonia
  • Flu
  • Whooping cough
  • Bacterial meningitis

Airborne: Germs travel through air currents, on dust and other particles that can spread over time and distance when a person:

  • Sneezes
  • Coughs

When the germs get placed into the air, they can travel with the flow of the air current for up to 3 hours. The infection/virus gets transmitted to others when a healthy person inhales the infected droplets, or they fall on a person’s face, eyes or nose.

Examples of infections spread by airborne transmission are:

  • Chickenpox
  • Norovirus
  • Measles
  • Influenza
  • Tuberculosis

COVID19 has been found to spread through droplet transmission of the virus, but it has been suggested by some researchers that COVID could spread by airborne transmission when there is a poor ventilation system. We know for sure that COVID19 spreads through droplets, and until we know for sure about airborne transmission, it is best to take as many precautions as we can. The things we are doing to prevent droplet transmission, like wearing a mask, social distancing between 3 to 6 feet apart, washing our hands, and limiting time indoors with other people will certainly help limit the spread of COVID19. It’s important that we all continue to stay up to date on the WHO and CDC guidelines on how to prevent the spread of COVID19.


Laura Kendrick is a Radiation Therapist at Penn Medicine in the department of Radiation Oncology for 9 years. She completed her Bachelor’s Degree in Radiation Therapy from Gwynedd-Mercy University and her Master’s Degree in Healthcare Administration from St. Joseph’s University. Laura has extensive experience in proton therapy, training of radiation therapist’s both domestic and internationally and has created multiple proton training videos for different vendors. Laura has been with Oncolink since 2017, but joined part-time in 2020 as Global Education Coordinator and is currently developing virtual reality training modules to train radiation therapist around the world.

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,434ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...

Καρκίνος: Ευεργετική για τους καρκινοπαθείς η άσκηση

Σημαντικά ωφέλη προσφέρει η άσκηση, ακόμη και σε ασθενείς με καρκίνο. Οι περισσότεροι ασθενείς αγνοούν τα οφέλη που μπορεί να έχει γι’ αυτούς η συχνή...

Prostate Cancer

The article is provided by Scientific Communications Officer of NIPD Genetics, Ms Marina Charitou (MSc) Prostate Cancer Awareness Prostate cancer is the second most common cancer...
- Advertisment -

Ροή Ειδήσεων

The Combination of Nivolumab and Cabozantinib Provides a New First-Line Treatment Option in Advanced Clear Cell RCC

Efficacy data with nivolumab plus cabozantinib showing improved survival and response rates, together with an acceptable safety profile presented by Prof. Toni K. Choueiri...

News digest – calorie guidelines, reduced lung cancer referrals and COVID-19’s impact on cancer services

Image was taken before the coronavirus pandemic. Urgent lung cancer referrals down during lockdown Of all cancer types, those with suspected lung cancer were the...

“If there is an under-representation of ethnic minority communities, there will be a lack of understanding”

Nikki and her son Amarvir, who was diagnosed with acute lymphoblastic leukaemia in 2010. We spoke to Siobhan, Nikki and Jessica about their experiences...

How to Strengthen Your Immune System: Part 2

Yesterday, we learned how certain foods and changes to our diet can help boost our immune system, which is especially important during this pandemic....

ACS’s Updated Cervical Cancer Screening Guidelines Explained

September 18, 2020, by NCI Staff A cervical specimen with a pap stain that identifies cervical cancer. Credit: National Cancer Institute Routine cervical cancer screening is very...

Access to Cancer Medicines and Clinical Trials Show Stark Variations Across Europe [ESMO Press Release]

LBA66_PR - Disparities in access to oncology clinical trials in Europe in the period 2009-2019 A. Carneiro1, T.M.S. Amaral2, M. Brandao3, M. Scheffler4, K. Bol5,...